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Introduction
Menopausal transition is a period of dynamic changes 
in reproductive and non-reproductive tissues so therefore 
it is considered to play a leading role in biological and 
health condition of an aging woman. During menopausal 
transition, the aging is as important as menopause1. Meno-
pausal transition, during its period, shall go through pre-
menopause and perimenopause stages, in order to reach 
finally the menopausal stage. If we neglect the fact that 
the average age for menopause is 51.4, we can concluded 
then that women spend one-third of their lives in post-
menopausal stage. Hormonal profile of menopausal transi-
tion is changing. Higher basal FSH in normal cycles of 
women is related to unfavourable lipids level and increased 
cardiovascular risks2. In menopause, metabolic changes 
in various tissues and organs occur as a result of changed 
hormonal profile3. Transition to menopause includes cen-
tral neuroendocrine changes as well as changes within the 
ovarii, the most characteristic of which is the absolute de-
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A B S T R A C T
Menopausal transition is a period characterised by psychic, somatic changes as well as changes in reproductive capa-
bilities of a woman as a consequence of ovarian’s function termination. Menopausal transition includes the stage of pre-
menopause and perimenopause, to reach finally the menopause stage itself. The aim of this study is to determine the 
differences in HDL concentrations at women in premenopause, perimenopause and postmenopause, and to determine the 
connection between BMI and WHR with HLD concentrations during the menopausal transition, as well as to determine 
the relation between menarche and length of reproductive age with HDL concentrations in menopausal transition. The 
assesses included in this study were aged from 40 to 55, with average age 48.1 ± 3.9 years. The biggest average HDL 
value was found at the group of postmenopausal assessees(1.65 mmol/L), and in comparison with the values in other two 
groups, there is a significant difference (F=4.23, p=0.016). Based on the obtained results, we cannot conclude that there 
is a significant relation between menarche and length of reproductive age and HDL among the premenopausal and post-
menopausal assessees. There is also a significant difference between WHR and HDL among the premenopausal and 
perimenopausal assesses. In this study, we obtained astonishing result in comparison with the studies and researches 
done so far, primarily referring to increased HDL at perimenopausal and postmenopausal assessees.
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crease of folicles’ number. The influence of oestrogen to 
lipid metabolism is evident in both, physiological status 
dependant on life age, as well as in psychological condi-
tions. Oestrogens stimulate synthesis of triglycerides in 
liver and decrease the hepatic triglyceride lipase activity 
(HTGL), as well as lipoprotein lipase activity (LPL). Due 
to such impact, oestrogens lead to increased endogenous 
status of triglycerides and very low density lipoproteins, 
VLDL, as well as decrease removal of those particles from 
circulation. Oestrogens increase the HDL cholesterol level 
and also increase the protein synthesis in liver, as well as 
the apolipoprotein A (apo A) which makes a part of HDL. 
Oestrogens have a very favourable impact to the level of 
atherogenic LDL particles4. HDL metabolism is partially 
connected through Apo lipoproteins with metabolism with 
triglyceride-rich hilomicrones and VLDL. HDL is biosyn-
thetized in liver and small intestine, from where it is ex-
creted. It is considered that HDL reacts with probable 
HDL receptor in liver thus being removed from circulation, 
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and also transferring surplus cholesterol from peripheral 
cells to the liver. There is a significant relation between 
the age and changes in triglyceride levels, total choles-
terol and LDL, while BMI is closely related to the changes 
in the level of triglycerides, LDL, HDL5. Total cholesterol, 
LDL and apolipoprotein B (apo B) show partial increase a 
year before and a year after the last menstruation, while 
HDL level reaches its peak around menopausal phase, af-
ter which it decreases6. Only total cholesterol, LDL and 
apo B show essential increase in a year before and after 
the last menstruation, and that fact is similar in all ethni-
cal groups7. Elevated values of cholesterol, triglyceride, 
LDL, apo B and decreased values of HDL and apo A are 
the features of lipid profile in postmenopause. HDL con-
centration is much lower at the group of menopausal wom-
en8. Some studies9,10 showed significant differences in con-
centration of lipids and lipoproteins at menopausal women, 
while the latest researches11-13 are based on the assessment 
of changes in LDL and HDL structure and their possible 
impact to cardiovascular risk at menopausal women. With 
menopause, HDL concentration decreases and HDL struc-
ture changes. HDL2 concentration decreases, while HDL3 
concentration increases. HDL concentration is reversely 
proportional to the level of abdominal obesity14. Early men-
arche is related to increased body mass and higher resis-
tance to insulin. According to the latest studies, it affects 
the increase of HDL cholesterol and decreased level of tri-
glycerides, while longer reproductive period is also related 
to increased body mass, and opposite from the age of men-
arche occurrence, it is characterised by decreased level of 
HDL and all other cholesterols15.
Goal of research
1.  Determine difference in HDL concentrations at 
women in premenopause, perimenopause and post-
menopause.
2.  Determine the connection between BMI and WHR 
and HDL concentrations during menopausal transi-
tion.
3.  Determine relation between menarche and duration 
of reproductive age and HDL concentration in meno-
pausal transition.
Assessees and Methods
This prospective, comparative study was conducted in 
period November 2012 – December 2013, and it included 
150 assessees in total, divided in three age groups from 
40 to 55.
Selection criteria for this study were: they do not take 
hormonal supplement therapy, they do not take medi-
cines that could affect the lipid profile, they do not smoke 
more than twenty cigarettes a day, BMI does not exceed 
35 kg/m².
The assessees were processed in three phases: inter-
view, blood sampling, measuring BMI and WHR. The as-
sessee group comprised women volunteers who agreed in 
writing to be included in the study. Each assessee was 
introduced with the character of the research.
Blood sampling was conducted in the Department for 
medical diagnostic of the public institution Health Centre 
in Tuzla by the trained employees. The vein blood sample 
was taken from cubital vein for the purpose of the analy-
sis, after which the blood was centrifuged, and HDL was 
determined from the obtained serum at the machine SIE-
MENS »Dimension RxL« using direct, »homogenous« 
method, where through reaction with special detergent we 
stabilize only HDL fraction from the others (LDL, VLDL). 
Quantitative determining of HDL is a combination of ul-
tracentrifugation and chemical precipitation where HDL 










HDL, mmol/L 1.48 (1.38, 1.57) 1.48 (1.39, 1.58) 1.65 (1.55, 1.75) 0.016
Values are estimated arithmetical median values and related 95% reliability interval. Group I – premenopausal assessees; group II – peri-
menopausal assessees; group III – postmenopausal assessees.
TABLE 2
REGRESSION COEFFICIENT FOR HDL IN RELATIO TO MENARCHE
Group I Group II Group III
Regression 
coefficient
95% IP P value Regression 
coefficient
95% IP P value Regression 
coefficient
95% IP P value
HDL, mmol/L 0.005 –0.053, 0.063 0.870 –0.010 –0.058, 0.037 0.663 –0.013 –0.074, 0.047 0.666
Group I – premenopausal assesses; group II – perimenopausal assesses; group III – postmenopausal assesses.
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Body mass and height of assessees was measured at 
the scale with height meter »SECA«, after which the nutri-
tion status was estimated based on Qeuetelet index (De-
venport-Kaup modification) or BMI: body mass in kg/
height in m2. Based on the waste size measured at the 
narrowest part and hips size measured at the widest part, 
WHR was calculated: waist size (cm) / thighs size (cm). 
Evaluation of the nutrition status was done based on the 
Qeuetelet index (Devenport-Kaup modification) or BMI 
where: BMI= body mass in kg/ height in m².
Based on the waist size measured at the narrowest 
part and thighs size measured at the widest part, WHR 
was calculated using the following formula: WH ratio= 
waist size (cm)/ thighs size (cm).
To compare numeric variables among the assessees, we 
used the analysis of variance (ANOVA) or Kruskal-Wallis 
non-parametric alternative. Multiple pair comparisons 
were conducted using Tukey or Bonferroni test. Variable 
values were presented as estimated arithmetic median 
values with relevant 95% reliability interval. Equality 
between noticed and expected frequency of category vari-
ables were tested with hi-square test. The results are pre-
sented as regression coefficients with related 95% reli-
ability interval (IP). At log-transformed variables, 
regression coefficients are reversely transformed. Statisti-
cal importance was confirmed at p<0.05. For data process-
ing, we used statistical programme PASW 18 (SPSS Inc., 
Chicago, Illinois, SAD).
Results
The assessees included in the study aged from 40 to 
55, with average age 48.1 ± 3.9. The age statistically dif-
fered among the groups: the perimenopausal assessees 
were two years older in average than the premenopausal 
ones (95% IP: 0.6-3.5 years), and the postmenopausal as-
sessees were four years older in average than the peri-
menopausal ones (95% IP: 2.6-5.4 years). There was sig-
nificant variability between medium HDL concentrations 
in three study groups (Table 1). The biggest average HDL 
value was in the postmenopausal group of assessees (1.65 
mmol/L), and in comparison with the values in other two 
groups, there is a significant difference (F=4.23, p=0.016). 
Multiple pair comparisons showed higher medium con-
centration at the postmenopausal assessees in relation to 
the premenopausal assessees (medium difference = 0.17 
mmol/L, p=0.029). Higher medium HDL concentrations 
were also noticed at postmenopausal assessees in relation 
to perimenopausal assessees (medium difference = 
0.16mmol/L, p=0.041). The results of the analysis of rela-
tion between menarche and HDL cholesterol concentra-
tion at the assessees, conducted utilizing bivarian linear 
regression model, are presented in the table 2. Based on 
the obtained regression coefficients and related P values, 
it may be concluded that there is a significant relation 
between menarche and HDL at the premenopausal, peri-
menopausal and postmenopausal assessees (Table 2). 
There is a significant negative relation between BMI and 
HDL at the premenopausal assessees (Table 3). If the 
regression coefficient was standardized to interquartile 
value of change in BMI (IQR=5), the difference of 0.18 
mmol/L would be suggested in medium HDL concentra-
tion between low and high BMI. Multivariate regression 
analysis would show that BMI affects HDL concentration. 
There is a significant negative relation between WHR and 
HDL at the premenopausal and perimenopausal assesses 
(Table 4). At WHR change for 0.05, regression coefficient 
shows the difference of 0.11 mmol/L in medium HDL con-
centration at premenopausal assessees, and the difference 
of 0.09 mmol/L in medium HDL concentration at peri-
menopausal assessees.
TABLE 3
REGRESSION COEFFICIENT FOR HDL IN RELATION TO BMI
Group I Group II Group III
Regression 
coefficient 95% IP P value
Regression 
coefficient 95% IP P value
Regression 
coefficient 95% IP P value
HDL, mmol/L –0.035 –0.057, –0.012 0.004 –0.018 –0.042, 0.006 0.143 0.020 –0.009, 0.050 0.177
Group I – premenopausal assesses; group II – perimenopausal assesses; group III – postmenopausal assesses.
 
TABLE 4
REGRESSION COEFFICIENT FOR HDL IN RELATIO TO WHR, CALCULATED TO WHR CHANGES FOR 0.05
Group I Group II Group III
Regression 
coefficient 95% IP P value
Regression 
coefficient 95% IP P value
Regression 
coefficient 95% IP P value
HDL, mmol/L –0.105 –0.186, –0.023 0.013 –0.089 –0.144, –0.034 0.002 0.017 –0.069, 0.102 0.692
Group I- premenopausal assesses; group II- perimenopausal assesses; group III- postmenopausal assesses.
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pause, which is also confirmed by the results of this study. 
Although this does not comply with the previous studies 
which show a gradual post-menopausal decrease of 
HDL22,23, the noticed trend complies with other studies, 
showing a gradual increase between pre-perimenopause 
and late perimenopause24. A small prospective study came 
to a conclusion that HDL reached maximum values, and 
then decreased between pre and post menopause24. Since 
not so long ago, it was generally accepted that HDL cho-
lesterol values decrease with menopause. However, latest 
studies show different results. Postmenopausal women 
have higher HDL values than premenopausal women and 
according to the results of the latest studies, there was no 
difference between perimenopausal and postmenopausal 
women. Menopause is related with HDL elevation, so that 
higher postmenopausal risk for cardiovascular diseases 
is not related to HDL values. HDL values are higher in 
perimenopause than in premenopause and late meno-
pause. Perimenopausal profile is closely related with el-
evated HDL cholesterol levels. The study in Islamabad25, 
which analysed the HDL cholesterol level at premeno-
pausal and postmenopausal assessees in relation to es-
tradiol level, showed a decrease of HDL at postmenopaus-
al assessees in comparison with the premenopausal 
assessees. The conclusion of that study is that HDL is an 
independent risk factor for coronary diseases, which is 
contrary to the results of this study and similar conse-
quent studies. MWMH Project23 noticed that there is a 
slight HDL cholesterol increase in a year before meno-
pause, followed by similar decrease in a year after the last 
menstruation. Epidemiologic studies indicate that there 
is no relation between the total cholesterol and brain 
stroke risk, but little attention is paid to HDL. Severity 
of literature proofs supports inverse relation between 
HDL values and brain stroke or carotid atherosclerosis, 
but more data are needed to strongly determine that pro-
tective effect26. This study demonstrated a permanent 
increase of HDL cholesterol from premenopause to post-
menopause, with particularly emphasised differences 
between the premenopausal and postmenopausal assess-
ees. Additional follow-up is needed to determine whether 
HDL noticed in late postmenopause would return to pre-
menopausal levels. In similar study27, the results showed 
much higher HDL cholesterol level at postmenopausal as-
sessees than at premenopausal assessees. The obtained 
results in this study, as well as the results of the Study of 
Women’s Health Across the Nation Heart women28, indi-
cate that protective effect of HDL may be decreased at 
women in menopausal transition. The future studies 
should assess could it be due to the changes in HDL par-
ticles size, functionality or relation of changes with other 
lipids and lipoproteins. Considering the well-known fact 
that non-atrogenous HDL related to apo A has the choles-
terol clearance function from artery walls, that it breaks 
the disposal of aterogenous lipoproteins, based on the ob-
tained results we cannot conclude that HDL is responsi-
ble for increased risk of cardiovascular diseases during 
menopausal transition. Significant result of this study, 
when it comes to HDL, confirms only some of the studies 
conducted so far.
Discussion
Numerous studies have been addressing the trend of 
HDL cholesterol value during menopausal transition. The 
average age in time of the last menstruation at the as-
sesses from this study was 48 years of age, and the lit-
erature so far15 has suggested that menopause usually 
occurs at the age 51, and that it has not changed for a long 
period of time. Although the lipid profiles are inclined to 
deterioration with age, it is not completely clear whether 
such changes are related to age and life style, or are in-
fluenced by other aspects of aging. The age is important 
independent predictor for LDL and total cholesterol at 
women, but it does not have such an influence as body 
structure and life style affecting the HDL, LDL and tri-
glyceride level at women16. One of the objectives of this 
study was to determine the relation between BMI and 
WHR and HDL concentration at the assessees in meno-
pausal transition, and the results of this study show that 
there is a negative relation between BMI and HDL in 
premenopause. We have determined only a significant 
negative relation between WHR and HDL cholesterol at 
the premenopausal and perimenopausal assesses. At pre-
menopausal women, WHR has a significant negative cor-
relation with HDL concentration8. The results of the re-
searches done within the comprehensive study 
implemented by the National Health and Nutrition Ex-
amination Survey among the assessees aged 35-60 in 
period 1999-20021 showed that there are no significant 
differences at total level of cholesterol, triglycerides, 
HDL, LDL cholesterol adjusted to the age, among meno-
pausal periods at women with normal BMI. A difference 
in HDL cholesterol values was noticed at groups with nor-
mal and higher BMI. Therefore, it is important to note 
that regardless the known and characteristic hormonal 
profile in menopausal transition, we obtained in this 
study a surprising result in comparison with the re-
searches and studies conducted so far, primarily related 
to increased HDL at perimenopausal and postmenopaus-
al assessees. So, the total cholesterol level increases with 
menopause, LDL share changes and increases, while 
HDL does not change17. The women who gave birth to 
children usually have lower HDL level than women who 
did not give a birth18. Menopause has unfavourable im-
pact to lipids metabolism, particularly to total choles-
terol values, which mainly increases through menopaus-
al transition, although the biggest problem mentioned is 
decrease of HDL cholesterol5. The results of a big study 
conducted at 9309 women show that menopause influ-
ences the level of lipids and lipoproteins. From premeno-
pause to postmenopause there is a significant increase of 
total cholesterol, LDL, triglycerides, but there are no sig-
nificant changes in HDL19. At postmenopausal women, 
HDL is lower than at premenopausal women20, which 
does not comply with our results.
In period 1995-2004, the SWAN study was implement-
ed at 2659 women who were followed-up during 7 year 
period and at whom the lipid changes mainly occurred in 
later menopausal stages21. HDL cholesterol also reached 
the maximum in late perimenopause and early postmeno-
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Conclusions
1.  HDL increases during menopausal transition and 
has the highest concentrations at postmenopausal 
assesses.
2.  BMI with HDL concentration has a negative correla-
tion in premenopause.
3.  WHR has a negative correlation with HDL concen-
tration in premenopause and perimenopause.
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KONCENTRACIJA LIPOPROTEINA VISOKE GUSTOĆE U MENOPAUZALNOJ TRANZICIJI
S A Ž E T A K
Menopauzalna tranzicija je period koji karakterišu psihičke, somatske i promjene u reproduktivnoj sposobnosti žene 
a nastaje kao posljedica gašenja ovarijalne funkcije. Menopauzalna tranzicija će u svom trajanju preći preko premeno-
pauze i perimenopauze, da bi došla do same menopauze. Cilj istraživanja je bio utvrditi razlike u koncentracijama HDL 
kod žena u premenopauzi, perimenopauzi i postmenopauzi, utvrditi povezanost BMI i WHR sa koncentracijama HDL 
tokom menopauzalne tranzicije, te utvrditi povezanost menarhe i dužine reproduktivne dobi sa koncentracijama HDL 
u menopauzalnoj tranziciji. Ispitanice, uključene u studiju, su bile stare od 40 do 55 godina, s prosječnom starošću od 
48.1 ± 3.9 godine. Najveća prosječna vrijednost HDL-a nađena je u grupi ispitanica koje su u postmenopauzi (1.65 
mmol/L), i u odnosu na vrijednosti u druge dvije grupe postoji značajna signifikantna razlika (F=4.23, p=0.016). Na 
osnovu dobijenih rezultata ne možemo zaključiti da postoji značajan odnos između menarhe i dužine reproduktivne dobi 
sa HDL kod ispitanica u premenopauzi, perimenopauzi i postmenopauzi. Postoji značajan negativan odnos između BMI 
i HDL kod ispitanica u premenopauzi, a multivariatnom regresijskom analizom se pokazalo da BMI utiče na koncen-
traciju HDL. Značajan je i negativan odnos između WHR i HDL kod ispitanica u premenopauzi i perimenopauzi. U ovom 
istraživanju smo dobili iznenađujući rezultat u odnosu na dosadašnja istraživanja, koji se prije svega odnosi na povećan 
HDL u perimenopauzalnih i postmenopauzalnih ispitanica.
